Edwards Lifesciences (EW) Capital Expenditures (2009 - 2026)

Edwards Lifesciences has reported Capital Expenditures for 18 years, with the latest figure at $66.9 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 35.7% year-over-year to $66.9 million in Q2 2026; TTM through Jun 2026 was $286.7 million, a 38.5% increase from a year earlier, with the FY2025 full-year figure at $260.2 million, up 3.09% from the prior year.
• Capital Expenditures was $66.9 million for Q2 2026 at Edwards Lifesciences, up from $64.9 million in the prior quarter.
• The five-year high for Capital Expenditures was $97.4 million in Q4 2025, with the low at $43.1 million in Q2 2022.
• Average Capital Expenditures over 5 years is $63.4 million, with a median of $60.7 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 43.6% in 2024, then jumped 95.58% in 2025.
• Over 5 years, Capital Expenditures stood at $68.9 million in 2022, then increased by 28.16% to $88.3 million in 2023, then plunged by 43.6% to $49.8 million in 2024, then surged by 95.58% to $97.4 million in 2025, then slumped by 31.31% to $66.9 million in 2026.
• The last three Capital Expenditures figures came in at $66.9 million (Q2 2026), $64.9 million (Q1 2026), and $97.4 million (Q4 2025), per Business Quant data.